Exscientia Agrees To Acquire GT Apeiron's Share Of Its Oral CDK7 Inhibitor Program, Gaining Full Control Of GTAEXS617 And All Related Intellectual Property; To Pay GT Apeiron $10M Upfront Cash
Portfolio Pulse from Benzinga Newsdesk
Exscientia has agreed to acquire GT Apeiron's share of its oral CDK7 inhibitor program, gaining full control of GTAEXS617 and all related intellectual property. Exscientia will pay GT Apeiron $10 million upfront in cash and $10 million in equity, and will take on all existing development costs. The monotherapy dose escalation phase of the ELUCIDATE trial is progressing well, with data expected in the second half of 2024. Exscientia's cash runway is expected to extend well into 2027.
July 18, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exscientia has acquired full control of the oral CDK7 inhibitor program from GT Apeiron, including GTAEXS617 and related IP, for $10M in cash and $10M in equity. The ELUCIDATE trial is progressing well, with data expected in H2 2024. Exscientia's cash runway extends into 2027.
The acquisition gives Exscientia full control over a promising drug candidate, which could lead to significant future revenues if successful. The ongoing trial is progressing well, and the company's cash runway is secure, indicating strong financial health.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100